Search

Your search keyword '"Cescon, David"' showing total 550 results
Start Over Author "Cescon, David"
550 results on '"Cescon, David"'

2. PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

Author

Lin, Chang-Ching, Chang, Tsung-Cheng, Wang, Yunguan, Guo, Lei, Gao, Yunpeng, Bikorimana, Emmanuel, Lemoff, Andrew, Fang, Yisheng V., Zhang, He, Zhang, Yanfeng, Ye, Dan, Soria-Bretones, Isabel, Servetto, Alberto, Lee, Kyung-min, Luo, Xuemei, Otto, Joseph J., Akamatsu, Hiroaki, Napolitano, Fabiana, Mani, Ram, Cescon, David W., Xu, Lin, Xie, Yang, Mendell, Joshua T., Hanker, Ariella B., and Arteaga, Carlos L.

Published
2024
Full Text
View/download PDF

5. Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor TypesDeterminants of Pembrolizumab Response in Solid Tumors

Author

Cristescu, Razvan, Nebozhyn, Michael, Zhang, Chunsheng, Albright, Andrew, Kobie, Julie, Huang, Lingkang, Zhao, Qing, Wang, Anran, Ma, Hua, Cao, Z Alexander, Morrissey, Michael, Ribas, Antoni, Grivas, Petros, Cescon, David W, McClanahan, Terrill K, Snyder, Alexandra, Ayers, Mark, Lunceford, Jared, and Loboda, Andrey

Subjects
Genetics, Cancer, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Good Health and Well Being, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Humans, Neoplasms, RNA, Transcriptome, Transforming Growth Factor beta, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeTo explore relationships between biological gene expression signatures and pembrolizumab response.Experimental designRNA-sequencing data on baseline tumor tissue from 1,188 patients across seven tumor types treated with pembrolizumab monotherapy in nine clinical trials were used. A total of 11 prespecified gene expression signatures [18-gene T-cell-inflamed gene expression profile (TcellinfGEP), angiogenesis, hypoxia, glycolysis, proliferation, MYC, RAS, granulocytic myeloid-derived suppressor cell (gMDSC), monocytic myeloid-derived suppressor cell (mMDSC), stroma/epithelial-to-mesenchymal transition (EMT)/TGFβ, and WNT] were evaluated for their relationship to objective response rate (per RECIST, version 1.1). Logistic regression analysis of response for consensus signatures was adjusted for tumor type, Eastern Cooperative Oncology Group performance status, and TcellinfGEP, an approach equivalent to evaluating the association between response and the residuals of consensus signatures after detrending them for their relationship with the TcellinfGEP (previously identified as a determinant of pembrolizumab response) and tumor type. Testing of the 10 prespecified non-TcellinfGEP consensus signatures for negative association [except proliferation (hypothesized positive association)] with response was adjusted for multiplicity.ResultsCovariance patterns of the 11 signatures (including TcellinfGEP) identified in Merck-Moffitt and The Cancer Genome Atlas datasets showed highly concordant coexpression patterns in the RNA-sequencing data from pembrolizumab trials. TcellinfGEP was positively associated with response; signatures for angiogenesis, mMDSC, and stroma/EMT/TGFβ were negatively associated with response to pembrolizumab monotherapy.ConclusionsThese findings suggest that features beyond IFNγ-related T-cell inflammation may be relevant to anti-programmed death 1 monotherapy response and may define other axes of tumor biology as candidates for pembrolizumab combinations. See related commentary by Cho et al., p. 1479.

Published
2022

6. Differential DNA damage repair and PARP inhibitor vulnerability of the mammary epithelial lineages

Author

Kim, Hyeyeon, Aliar, Kazeera, Tharmapalan, Pirashaanthy, McCloskey, Curtis W., Kuttanamkuzhi, Abhijith, Grünwald, Barbara T., Palomero, Luis, Mahendralingam, Mathepan J., Waas, Matthew, Mer, Arvind S., Elliott, Mitchell J., Zhang, Bowen, Al-Zahrani, Khalid N., Langille, Ellen R., Parsons, Michael, Narala, Swami, Hofer, Stefan, Waterhouse, Paul D., Hakem, Razqallah, Haibe-Kains, Benjamin, Kislinger, Thomas, Schramek, Daniel, Cescon, David W., Pujana, Miquel A., Berman, Hal K., and Khokha, Rama

Published
2023
Full Text
View/download PDF

7. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer

Author

Wu, Qin, Nie, David Y., Ba-alawi, Wail, Ji, YiShuai, Zhang, ZiWen, Cruickshank, Jennifer, Haight, Jillian, Ciamponi, Felipe E., Chen, Jocelyn, Duan, Shili, Shen, Yudao, Liu, Jing, Marhon, Sajid A., Mehdipour, Parinaz, Szewczyk, Magdalena M., Dogan-Artun, Nergiz, Chen, WenJun, Zhang, Lan Xin, Deblois, Genevieve, Prinos, Panagiotis, Massirer, Katlin B., Barsyte-Lovejoy, Dalia, Jin, Jian, De Carvalho, Daniel D., Haibe-Kains, Benjamin, Wang, XiaoJia, Cescon, David W., Lupien, Mathieu, and Arrowsmith, Cheryl H.

Published
2022
Full Text
View/download PDF

8. Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial

Author

Veitch, Zachary W, Cescon, David W, Denny, Trisha, Yonemoto, Lisa-Maria, Fletcher, Graham, Brokx, Richard, Sampson, Peter, Li, Sze-Wan, Pugh, Trevor J, Bruce, Jeffrey, Bray, Mark R, Slamon, Dennis J, Mak, Tak W, Wainberg, Zev A, and Bedard, Philippe L

Subjects
Clinical Trials and Supportive Activities, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Agents, Dose-Response Relationship, Drug, Female, Humans, Indazoles, Indoles, Male, Middle Aged, Neoplasms, Neutropenia, Protein Serine-Threonine Kinases, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundCFI-400945 is a first-in-class oral inhibitor of polo-like kinase 4 (PLK4) that regulates centriole duplication. Primary objectives of this first-in-human phase 1 trial were to establish the safety and tolerability of CFI-400945 in patients with advanced solid tumours. Secondary objectives included pharmacokinetics, pharmacodynamics, efficacy, and recommended phase 2 dose (RP2D).MethodsContinuous daily oral dosing of CFI-400945 was evaluated using a 3+3 design guided by incidence of dose-limiting toxicities (DLTs) in the first 28-day cycle. Safety was assessed by CTCAE v4.0. ORR and CBR were evaluated using RECIST v1.1.ResultsForty-three patients were treated in dose escalation from 3 to 96 mg/day, and 9 were treated in 64 mg dose expansion. After DLT occurred at 96 and 72 mg, 64 mg was established as the RP2D. Neutropenia was a common high-grade (19%) treatment-related adverse event at ≥ 64 mg. Half-life of CFI-400945 was 9 h, with Cmax achieved 2-4 h following dosing. One PR (45 cycles, ongoing) and two SD ≥ 6 months were observed (ORR = 2%; CBR = 6%).ConclusionsCFI-400945 is well tolerated at 64 mg with dose-dependent neutropenia. Favourable pharmacokinetic profiles were achieved with daily dosing. Response rates were low without biomarker pre-selection. Disease-specific and combination studies are ongoing.Trial registrationClinical Trials Registration Number - NCT01954316 (Oct 1st, 2013).

Published
2019

11. Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies

Author

Hilton, John, Gelmon, Karen, Bedard, Philippe L., Tu, Dongsheng, Xu, Hong, Tinker, Anna V., Goodwin, Rachel, Laurie, Scott A., Jonker, Derek, Hansen, Aaron R., Veitch, Zachary W., Renouf, Daniel J., Hagerman, Linda, Lui, Hongbo, Chen, Bingshu, Kellar, Deb, Li, Irene, Lee, Sung-Eun, Kono, Takako, Cheng, Brian Y. C., Yap, Damian, Lai, Daniel, Beatty, Sean, Soong, John, Pritchard, Kathleen I., Soria-Bretones, Isabel, Chen, Eric, Feilotter, Harriet, Rushton, Moira, Seymour, Lesley, Aparicio, Samuel, and Cescon, David W.

Published
2022
Full Text
View/download PDF

18. Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory Analysis

Author

Loi, Sherene, Salgado, Roberto, Schmid, Peter, Cortes, Javier, Cescon, David W., Winer, Eric P., Toppmeyer, Deborah L., Rugo, Hope S., De Laurentiis, Michelino, Nanda, Rita, Iwata, Hiroji, Awada, Ahmad, Tan, Antoinette R., Sun, Yuan, Karantza, Vassiliki, Wang, Anran, Huang, Lingkang, Saadatpour, Assieh, Cristescu, Razvan, Yearley, Jennifer, Lunceford, Jared, Jelinic, Petar, and Adams, Sylvia

Published
2023
Full Text
View/download PDF

21. Clinical Activity of Mitogen-Activated Protein Kinase–Targeted Therapies in Patients With Non–V600 BRAF-Mutant Tumors

Author

Dankner, Matthew, Wang, Yifan, Fazelzad, Rouhi, Johnson, Benny, Nebhan, Caroline A., Dagogo-Jack, Ibiayi, Myall, Nathaniel J., Richtig, Georg, Bracht, Jillian W.P., Gerlinger, Marco, Shinozaki, Eiji, Yoshino, Takayuki, Kotani, Daisuke, Fangusaro, Jason R., Gautschi, Oliver, Mazieres, Julien, Sosman, Jeffrey A., Kopetz, Scott, Subbiah, Vivek, Davies, Michael A., Groover, Anna L., Sullivan, Ryan J., Flaherty, Keith T., Johnson, Douglas B., Benedetti, Andrea, Cescon, David W., Spreafico, Anna, Zogopoulos, George, and Rose, April A.N.

Published
2022
Full Text
View/download PDF

23. Data from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, primary, Morales Murilo, Serafin, primary, Layman, Rachel M., primary, Pluard, Timothy, primary, Yeo, Belinda, primary, Park, In Hae, primary, Provencher, Louise, primary, Kim, Sung-Bae, primary, Im, Young-Hyuck, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Hicks, Kirsty, primary, Zhang, Qu, primary, Barbash, Olena, primary, Khaled, Ahmed, primary, Horner, Thierry, primary, Dhar, Arindam, primary, Oliveira, Mafalda, primary, and Sparano, Joseph A., primary

Published
2024
Full Text
View/download PDF

24. Supplementary Data1 from A Phase I/II Study of GSK525762 Combined with Fulvestrant in Patients with Hormone Receptor–positive/HER2-negative Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, primary, Morales Murilo, Serafin, primary, Layman, Rachel M., primary, Pluard, Timothy, primary, Yeo, Belinda, primary, Park, In Hae, primary, Provencher, Louise, primary, Kim, Sung-Bae, primary, Im, Young-Hyuck, primary, Wyce, Anastasia, primary, Krishnatry, Anu Shilpa, primary, Hicks, Kirsty, primary, Zhang, Qu, primary, Barbash, Olena, primary, Khaled, Ahmed, primary, Horner, Thierry, primary, Dhar, Arindam, primary, Oliveira, Mafalda, primary, and Sparano, Joseph A., primary

Published
2024
Full Text
View/download PDF

25. Identification of KIFC1 as a putative vulnerability in lung cancers with centrosome amplification

Author

Zhang, Christopher, primary, Wu, Benson, additional, Wu, Yin Fang, additional, di Ciano-Oliveira, Caterina, additional, Soria-Bretones, Isabel, additional, Pham, Nhu-An, additional, Elia, Andrew J., additional, Chari, Raj, additional, Lam, Wan L., additional, Bray, Mark R., additional, Mak, Tak W., additional, Tsao, Ming-Sound, additional, Cescon, David W., additional, and Thu, Kelsie L., additional

Published
2024
Full Text
View/download PDF

27. Health-Related Quality of Life With Pembrolizumab+Chemotherapy Versus Placebo+Chemotherapy for Advanced Triple-Negative Breast Cancer: KEYNOTE-355

Author

Cescon, David W, primary, Schmid, Peter, additional, Rugo, Hope S, additional, Im, Seock-Ah, additional, Yusof, Mastura Md, additional, Gallardo, Carlos, additional, Lipatov, Oleg, additional, Barrios, Carlos H, additional, Perez-Garcia, Jose, additional, Iwata, Hiroji, additional, Masuda, Norikazu, additional, Otero, Marco Torregroza, additional, Gokmen, Erhan, additional, Loi, Sherene, additional, Haiderali, Amin, additional, Zhou, Xuan, additional, Guo, Zifang, additional, Nguyen, Allison Martin, additional, and Cortes, Javier, additional

Published
2023
Full Text
View/download PDF

29. AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer

Author

Kubli, Shawn P., Bassi, Christian, Roux, Cecilia, Wakeham, Andrew, Göbl, Christoph, Zhou, Wenjing, Jafari, Soode Moghadas, Snow, Bryan, Jones, Lisa, Palomero, Luis, Thu, Kelsie L., Cassetta, Luca, Soong, Daniel, Berger, Thorsten, Ramachandran, Parameswaran, Baniasadi, Shakiba P., Duncan, Gordon, Lindzen, Moshit, Yarden, Yosef, Herranz, Carmen, Lazaro, Conxi, Chu, Mandy F., Haight, Jillian, Tinto, Paul, Silvester, Jennifer, Cescon, David W., Petit, Anna, Pettersson, Sven, Pollard, Jeffrey W., Mak, Tak W., Pujana, Miguel A., Cappello, Paola, and Gorrini, Chiara

Published
2019

32. Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355.

Author

Cescon, David W, Schmid, Peter, Rugo, Hope S, Im, Seock-Ah, Yusof, Mastura Md., Gallardo, Carlos, Lipatov, Oleg, Barrios, Carlos H, Perez-Garcia, Jose, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Gokmen, Erhan, Loi, Sherene, Haiderali, Amin, Zhou, Xuan, Guo, Zifang, Nguyen, Allison Martin, and Cortes, Javier

Subjects
*TRIPLE-negative breast cancer, *QUALITY of life, *PEMBROLIZUMAB, *PHYSICAL mobility, *HORMONE receptor positive breast cancer, *CANCER chemotherapy
Abstract

Background In KEYNOTE-355 (NCT02819518), the addition of pembrolizumab to chemotherapy led to statistically significant improvements in progression-free survival and overall survival in patients with advanced triple-negative breast cancer with tumor programmed cell death ligand 1 (PD-L1) combined positive score of at least 10. We report patient-reported outcomes from KEYNOTE-355. Methods Patients were randomly assigned 2:1 to pembrolizumab 200 mg or placebo every 3 weeks for up to 35 cycles plus investigator's choice chemotherapy (nab-paclitaxel, paclitaxel, or gemcitabine plus carboplatin). The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 (QLQ-C30), Breast Cancer–Specific Quality of Life Questionnaire, and EuroQol 5-Dimension questionnaire visual analog scale were prespecified. Patient-reported outcomes were analyzed for patients who received at least 1 dose of study treatment and completed at least 1 patient-reported outcome assessment. Changes in patient-reported outcome scores from baseline were assessed at week 15 (latest time point at which completion and compliance rates were at least 60% and at least 80%, respectively). Time to deterioration in patient-reported outcomes was defined as time to first onset of at least a 10-point worsening in score from baseline. Results Patient-reported outcome analyses included 317 patients with tumor PD-L1 combined positive score of at least 10 (pembrolizumab plus chemotherapy: n = 217; placebo plus chemotherapy: n = 100). There were no between-group differences in change from baseline to week 15 in QLQ-C30 global health status/quality of life (QOL; least-squares mean difference = −1.81, 95% confidence interval [CI] = −6.92 to 3.30), emotional functioning (least-squares mean difference = −1.43, 95% CI = −7.03 to 4.16), physical functioning (least-squares mean difference = −1.05, 95% CI = −6.59 to 4.50), or EuroQol 5-Dimension questionnaire visual analog scale (least-squares mean difference = 0.18, 95% CI = −5.04 to 5.39) and no between-group difference in time to deterioration in QLQ-C30 global health status/QOL, emotional functioning, or physical functioning. Conclusions Together with the efficacy and safety findings, patient-reported outcome results from KEYNOTE-355 support pembrolizumab plus chemotherapy as a standard of care for patients with advanced triple-negative breast cancer with tumor PD-L1 expression (combined positive score ≥10). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance.

Author

Kohan, Andres A., Lupien, Mathieu, Cescon, David, Deblois, Geneviève, Ventura, Manuela, Metser, Ur, and Veit-Haibach, Patrick

Subjects
TRIPLE-negative breast cancer, DRUG resistance, AUTORADIOGRAPHY, POSITRON emission tomography, ANIMAL models in research
Abstract

Purpose: Test the feasibility of an image-based method to identify taxane resistance in mouse bearing triple-negative breast cancer (TNBC) tumor xenografts. Methods: Xenograft tumor-bearing mice from paclitaxel-sensitive and paclitaxel-resistant TNBC cells (MDA-MD-346) were generated by orthotopic injection into female NOD-SCID mice. When tumors reached 100–150 mm3, mice were scanned using [18F]choline PET/CT. Tumors were collected and sliced for autoradiography and immunofluorescence analysis. Quantitative data was analyzed accordingly. Results: From fifteen mice scanned, five had taxane-sensitive cell line tumors of which two underwent taxol-based treatment. From the remaining 10 mice with taxane-resistant cell line tumors, four underwent taxol-based treatment. Only 13 mice had the tumor sample analyzed histologically. When normalized to the blood pool, both cell lines showed differences in metabolic uptake before and after treatment. Conclusions: Treated and untreated taxane-sensitive and taxane-resistant cell lines have different metabolic properties that could be leveraged before the start of chemotherapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

34. A Phase I/II Study of GSK525762 Combined With Fulvestrant in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2−) Advanced or Metastatic Breast Cancer

Author

Cescon, David W., primary, Hilton, John, additional, Morales Murilo, Serafín, additional, Layman, Rachel M., additional, Pluard, Timothy, additional, Yeo, Belinda, additional, Park, In Hae, additional, Provencher, Louise, additional, Kim, Sung-Bae, additional, Im, Young-Hyuck, additional, Wyce, Anastasia, additional, Krishnatry, Anu Shilpa, additional, Hicks, Kirsty, additional, Zhang, Qu, additional, Barbash, Olena, additional, Khaled, Ahmed, additional, Horner, Thierry, additional, Dhar, Arindam, additional, Oliveira, Mafalda, additional, and Sparano, Joseph A., additional

Published
2023
Full Text
View/download PDF

35. Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic Lethality

Author

Lin, Peter, primary, Lourenco, Corey, additional, Cruickshank, Jennifer, additional, Palomero, Luis, additional, van Leeuwen, Jenna E., additional, Tong, Amy H. Y., additional, Chan, Katherine, additional, El Ghamrasni, Samah, additional, Pujana, Miquel Angel, additional, Cescon, David W., additional, Moffat, Jason, additional, and Penn, Linda Z., additional

Published
2023
Full Text
View/download PDF

36. TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

Author

Dent, Rebecca A, primary, Cescon, David W, additional, Bachelot, Thomas, additional, Jung, Kyung Hae, additional, Shao, Zhi-Ming, additional, Saji, Shigehira, additional, Traina, Tiffany A, additional, Vukovic, Petra, additional, Mapiye, Darlington, additional, Maxwell, Micah J, additional, Schmid, Peter, additional, and Cortés, Javier, additional

Published
2023
Full Text
View/download PDF

38. REPLY TO OEGEMA ET AL. : CFI-400945 and Polo-like kinase 4 inhibition

Author

Kawakami, Masanori, Mustachio, Lisa Maria, Zheng, Lin, Chen, Yulong, Rodriguez-Canales, Jaime, Mino, Barbara, Kurie, Jonathan M., Roszik, Jason, Villalobos, Pamela Andrea, Thu, Kelsie L., Silvester, Jennifer, Cescon, David W., Wistuba, Ignacio I., Mak, Tak W., Liu, Xi, and Dmitrovsky, Ethan

Published
2018

41. Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors

Author

Fuentes-Antrás, Jesús, primary, Martínez-Rodríguez, Ana, additional, Guevara-Hoyer, Kissy, additional, López-Cade, Igor, additional, Lorca, Víctor, additional, Pascual, Alejandro, additional, de Luna, Alicia, additional, Ramírez-Ruda, Carmen, additional, Swindell, Jennifer, additional, Flores, Paloma, additional, Lluch, Ana, additional, Cescon, David W., additional, Pérez-Segura, Pedro, additional, Ocaña, Alberto, additional, Jones, Frederick, additional, Moreno, Fernando, additional, García-Barberán, Vanesa, additional, and García-Sáenz, José Ángel, additional

Published
2023
Full Text
View/download PDF

43. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer

Author

Wu, Qin, ba-alawi, Wail, Deblois, Genevieve, Cruickshank, Jennifer, Duan, Shili, Lima-Fernandes, Evelyne, Haight, Jillian, Tonekaboni, Seyed Ali Madani, Fortier, Anne-Marie, Kuasne, Hellen, McKee, Trevor D., Mahmoud, Hassan, Kushida, Michelle, Cameron, Sarina, Dogan-Artun, Nergiz, Chen, WenJun, Nie, Yan, Zhang, Lan Xin, Vellanki, Ravi N., Zhou, Stanley, Prinos, Panagiotis, Wouters, Bradly G., Dirks, Peter B., Done, Susan J., Park, Morag, Cescon, David W., Haibe-Kains, Benjamin, Lupien, Mathieu, and Arrowsmith, Cheryl H.

Published
2020
Full Text
View/download PDF

46. Reply to Trudeau, M.; Fraser, B. The CADTH pCODR Expert Review Committee Process Explained. Comment on “Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895”

Author

Rayson, Daniel, primary, Gandhi, Sonal, additional, Joy, Anil A., additional, Brezden-Masley, Christine, additional, Gelmon, Karen A., additional, Sehdev, Sandeep, additional, Cescon, David, additional, and Chia, Stephen, additional

Published
2023
Full Text
View/download PDF

47. Supplementary Data from Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer

Author

Langille, Ellen, primary, Al-Zahrani, Khalid N., primary, Ma, Zhibo, primary, Liang, Minggao, primary, Uuskula-Reimand, Liis, primary, Espin, Roderic, primary, Teng, Katie, primary, Malik, Ahmad, primary, Bergholtz, Helga, primary, Ghamrasni, Samah El, primary, Afiuni-Zadeh, Somaieh, primary, Tsai, Ricky, primary, Alvi, Sana, primary, Elia, Andrew, primary, Lü, YiQing, primary, Oh, Robin H., primary, Kozma, Katelyn J., primary, Trcka, Daniel, primary, Narimatsu, Masahiro, primary, Liu, Jeff C., primary, Nguyen, Thomas, primary, Barutcu, Seda, primary, Loganathan, Sampath K., primary, Bremner, Rod, primary, Bader, Gary D., primary, Egan, Sean E., primary, Cescon, David W., primary, Sørlie, Therese, primary, Wrana, Jeffrey L., primary, Jackson, Hartland W., primary, Wilson, Michael D., primary, Witkiewicz, Agnieszka K., primary, Knudsen, Erik S., primary, Pujana, Miguel Angel, primary, Wahl, Geoffrey M., primary, and Schramek, Daniel, primary

Published
2023
Full Text
View/download PDF

49. Abstract 3934: PRMT5 is an actionable target in CDK4/6 inhibitor-resistant ER+/Rb-deficient breast cancer

Author

Lin, Chang-Ching, primary, Chang, Tsung-Cheng, additional, Wang, Yunguan, additional, Zhang, Yanfeng, additional, Lemoff, Andrew, additional, Fang, Yisheng V., additional, Zhang, He, additional, Ye, Dan, additional, Soria-Bretones, Isabel, additional, Servetto, Alberto, additional, Lee, Kyung-min, additional, Luo, Xuemei, additional, Otto, Joseph J., additional, Akamatsu, Hiroaki, additional, Cescon, David W., additional, Xu, Lin, additional, Xie, Yang, additional, Mendell, Joshua T., additional, Hanker, Ariella B., additional, and Arteaga, Carlos L., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results